Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

BMC Psychiatry

Research Article

Thomas Forst¹  Daniel Kopf²  Susanne Kraemer³  Anette Minarzyk³  Hans-Peter Hundemer³ 

[1] Institute for Clinical Research IKFE, Parcusstr. 8, 55116, Mainz, Germany;Kath. Marienkrankenhaus GmbH, Geriatrics Clinic, Alfredstr.9, 22087, Hamburg, Germany;Lilly Deutschland GmbH, Medical Department, Werner -Reimers-Str. 2-4, 61352, Bad Homburg, Germany;

关键词: Schizophrenia;    Antipsychotic Medication;    Schizophrenia Patient;    Primary Care Patient;    Antipsychotic Treatment;   

DOI  :  10.1186/1471-244X-11-173

 received in 2011-04-28, accepted in 2011-11-01,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThis observational study explored the prevalence of metabolic syndrome (MetS) in adult in- and outpatients with untreated or treated schizophrenia at baseline, and month-3 after initiation or switch of antipsychotic treatment.MethodsMetS-prevalence (AHA/NHLB-definition) was assessed and Clopper-Pearson 95% confidence intervals (CIs) were calculated. Factors associated with MetS were explored through univariate and multivariate logistic regressions (both visits).ResultsMetS-prevalence was 44.3% (CI 39.8;48.9) at baseline and 49.6% (CI 45.0;54.2) at month-3. Previously unmedicated patients showed the lowest baseline MetS-prevalence (24.7%, CI 18.3;32.1). MetS-prevalence was not significantly different, regardless if patients previously received typical or atypical antipsychotics. Increased MetS-risk was associated with somatic comorbidity and non-smoking at both visits, and with non-psychiatric co-medication, male sex, and increased C-reactive protein at month-3.ConclusionsAt baseline, MetS was most prevalent in patients with previous antipsychotic medication. Limited metabolic changes were observed 3 months after switch/initiation of antipsychotic therapy.Trial Registration NumberClinicalTrials.gov Identifier: n.a.

【 授权许可】

CC BY   
© Kraemer et al; licensee BioMed Central Ltd. 2011